Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Review

Switching to systemic therapy after locoregional treatment failure: Definition and best timing

Sadahisa Ogasawara, Yoshihiko Ooka, Keisuke Koroki, Susumu Maruta, Hiroaki Kanzaki, Kengo Kanayama, Kazufumi Kobayashi, Soichiro Kiyono, Masato Nakamura, Naoya Kanogawa, Tomoko Saito, Takayuki Kondo, Eiichiro Suzuki, Shingo Nakamoto, Akinobu Tawada, Tetsuhiro Chiba, Makoto Arai, Jun Kato, Naoya Kato

Clin Mol Hepatol. 2020;26(2):155-162. Published online January 15, 2020

DOI: https://doi.org/10.3350/cmh.2019.0021n

View: 10738 Download: 421 Web of Science: 45 Crossref: 41

Editorial

Transcriptomic signature in advanced hepatocellular carcinoma tissue to predict combination immunotherapy response

Hiroaki Kanzaki, Yujin Hoshida

Received August 28, 2024 Accepted August 29, 2024

DOI: https://doi.org/10.3350/cmh.2024.0726 [Accepted]

View: 365 Download: 34

Reply to Correspondence

Reply: Correspondence: “Transcriptomic signature in hepatocellular carcinoma to predict immunotherapy response.”

Hiroaki Kanzaki, Yujin Hoshida

Received October 8, 2024 Accepted October 9, 2024

DOI: https://doi.org/10.3350/cmh.2024.0886 [Accepted]

View: 313 Download: 11

1 |

Viewed By 5041	Examining the therapeutic landscape of beta-blockers in portal hypertension
Viewed By 4909	MAFLD: How is it different from NAFLD?
Viewed By 4419	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 4338	Global incidence and prevalence of nonalcoholic fatty liver disease
Viewed By 4287	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma

Cited By 248	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 197	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 145	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Cited By 137	MAFLD: How is it different from NAFLD?
Cited By 113	Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach

Search